Official ESCRS | European Society of Cataract & Refractive Surgeons
Vienna 2018 Delegate Registration Programme Exhibition Virtual Exhibition Satellites 2018 Survey


escrs app advert

A single-center, prospective study to report outcomes of arcuate incisions (AI) in FLACS

Search Title by author or title

Session Details

Session Title: Rotational Stability & Outcomes

Session Date/Time: Monday 24/09/2018 | 14:30-16:00

Paper Time: 15:32

Venue: Room A4

First Author: : D.Holland GERMANY

Co Author(s): :    I. Matthaei   M. Poelzl   F. Ruefer              

Abstract Details


To investigate the change in corneal and refractive astigmatism after AI performed in FLACS in patients undergoing cataract surgery.


nordBLICK Augenklinik Bellevue


LENSARTM femtosecond laser was used to perform anterior capsulotomy, lens fragmentation, and AI in eyes undergoing cataract surgery. Preoperative corneal astigmatism and manifest refraction were compared to post-operative data at 1, 3, 6, and 12 months. Rate of adverse events were reported.


Forty-seven eyes (24 OD) of 32 patients (27 F) with mean age 69.3 ± 9.7 years were included. Mean refractive astigmatism was reduced from -1.50 ± 0.96 D pre-operatively to -0.60 ±0.52 D at one-year follow-up (p<0.001). At 1-year, 53.9% had less than 0.50D of refractive astigmatism and 84.6% had less than 1.00D of refractive astigmatism. Corneal astigmatism was reduced from 1.45 ± 0.61 D pre-operatively to 0.93 ± 0.54 D at one-year follow-up (p<0.001). There was no change in either refractive astigmatism (P>0.63) or corneal astigmatism (P>0.25) between the 3, 6 and 12-months visits. No adverse events were reported.


AI are effective in reducing astigmatism in eyes undergoing cataract refractive surgery. Refractive and corneal astigmatism were stable from the 3-month visit. The difference between the change of corneal astigmatism and refractive astigmatism has to be explained in further examinations. The effect of the AI may be improved by changing the normogram which has to be investigated in a second trial.

Financial Disclosure:


Back to previous